Interpace Biosciences, Inc. Common Stock
IDXG
IDXG was delisted on the 24th of February, 2021.
26 hedge funds and large institutions have $36.5M invested in Interpace Biosciences, Inc. Common Stock in 2013 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 9 increasing their positions, 4 reducing their positions, and 4 closing their positions.
125% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 4
2% less capital invested
Capital invested by funds: $37.1M → $36.5M (-$596K)
10% less funds holding
Funds holding: 29 → 26 (-3)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HA
Heartland Advisors
Milwaukee,
Wisconsin
|
+$1.43M |
| 2 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$752K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$122K |
| 4 |
GT
Glenmede Trust
Philadelphia,
Pennsylvania
|
+$99.7K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$31.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KSC
Kendall Square Capital
San Francisco,
California
|
-$2.54M |
| 2 |
WI
WHV Investments
San Francisco,
California
|
-$219K |
| 3 |
Goldman Sachs
New York
|
-$74K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$72.3K |
| 5 |
LMF
LMR Master Fund
Grand Cayman,
Cayman Islands
|
-$58K |
IDXG Hedge Fund Activity: Q4 2013 in Review
26 of the 3,459 institutional investors tracked by Wall St. Rank reported a position in Interpace Biosciences, Inc. Common Stock (IDXG) for Q4 2013, worth a combined $36.5M — down 1.6% from $37.1M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of IDXG and 2 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 9 added.
The largest buyer was Heartland Advisors, adding an estimated $1.43M. The largest seller was Kendall Square Capital, exiting entirely with an estimated $2.54M sold.
- 26 institutional investors held Interpace Biosciences, Inc. Common Stock (IDXG) as of Q4 2013, down from 29 in Q3 2013.
- Funds reported $36.5M of Interpace Biosciences, Inc. Common Stock stock for Q4 2013, down 1.6% quarter-over-quarter.
- 2 funds opened new Interpace Biosciences, Inc. Common Stock positions in Q4 2013 and 4 closed out, a net change of -2 holders.
- The largest Interpace Biosciences, Inc. Common Stock buyer in Q4 2013 was Heartland Advisors, an estimated $1.43M added.
- The largest Interpace Biosciences, Inc. Common Stock seller in Q4 2013 was Kendall Square Capital, an estimated $2.54M sold.
Based on aggregated 13F filings for Q4 2013.